An Investigator-initiated Phase I study of replacement therapy with a natural-type micro RNA for patients with malignant pleural mesothelioma (MIRX002-02 repeated dose study) - MIRX002-02

开始日期2022-04-25

申办/合作机构-

100 项与 MIRX-002 相关的临床结果

登录后查看更多信息

100 项与 MIRX-002 相关的转化医学

登录后查看更多信息

100 项与 MIRX-002 相关的专利（医药）

登录后查看更多信息

386

项与 MIRX-002 相关的文献（医药）

2024-05-02·Interdisciplinary CardioVascular and Thoracic Surgery

Antithrombotic therapy after heart valve surgery: contemporary practice in the UK

Article

作者: Maier, Rebecca ; Akowuah, Enoch ; Laskar, Nabila ; Shah, Benoy Nalin ; Chambers, John B ; Cartwright, Neil ; Kendall, Simon ; Briffa, Norman P ; Bayliss, Christopher D ; Kirmani, Bilal H

AbstractOBJECTIVESThere is a lack of high-quality data informing the optimal antithrombotic drug strategy following bioprosthetic heart valve replacement or valve repair. Disparity in recommendations from international guidelines reflects this. This study aimed to document current patterns of antithrombotic prescribing after heart valve surgery in the UK.METHODSAll UK consultant cardiac surgeons were e-mailed a custom-designed survey. The use of oral anticoagulant (OAC) and/or antiplatelet drugs following bioprosthetic aortic valve replacement or mitral valve replacement, or mitral valve repair (MVrep), for patients in sinus rhythm, without additional indications for antithrombotic medication, was assessed. Additionally, we evaluated anticoagulant choice following MVrep in patients with atrial fibrillation.RESULTSWe identified 260 UK consultant cardiac surgeons from 36 units, of whom 103 (40%) responded, with 33 units (92%) having at least 1 respondent. The greatest consensus was for patients undergoing bioprosthetic aortic valve replacement, in which 76% of surgeons favour initial antiplatelet therapy and 53% prescribe lifelong treatment. Only 8% recommend initial OAC. After bioprosthetic mitral valve replacement, 48% of surgeons use an initial OAC strategy (versus 42% antiplatelet), with 66% subsequently prescribing lifelong antiplatelet therapy. After MVrep, recommendations were lifelong antiplatelet agent alone (34%) or following 3 months OAC (20%), no antithrombotic agent (20%), or 3 months OAC (16%). After MVrep for patients with established atrial fibrillation, surgeons recommend warfarin (38%), a direct oral anticoagulant (37%) or have no preference between the 2 (25%).CONCLUSIONSThere is considerable variation in the use of antithrombotic drugs after heart valve surgery in the UK and a lack of high-quality evidence to guide practice, underscoring the need for randomized studies.

2024-05-01·Kyobu geka. The Japanese journal of thoracic surgery

[Redo Mitral Valve Replacement for Prosthetic Valve Endocarditis in a Patient with End Stage Colon Cancer:Report of a Case].

Article

作者: Orii, Kouan ; Abe, Takayuki ; Kondo, Taichi ; Hirai, Yuuki

Prosthetic valve endocarditis (PVE) is rare but devastating. A 69-year old man admitted for active endocarditis caused by Streptococcus pasteurianus. Antibiotic therapy was started, but the patient developed bowel obstruction owing to cancer with multiple liver metastases, and underwent transverse colectomy. Following colectomy, antibiotic agent was given continued for 4 weeks after and mitral valve replacement( MVR) using a bioprosthesis was performed. Oral antibiotic therapy was continued for six months after MVR to avoid infection recurrence. One year after MVR, the size of multiple liver metastases increased despite oral anticancer drugs administration. A totally implantable central venous access port( CV port) was placed and intravenous chemotherapy was started for progressive metastatic colorectal cancer. But the CV port was removed due to device infection caused by multiple drug resistant Staphyrococcus lugdunensis one month later, but the patient developed prosthetic valve endocarditits( PVE) due to the same bacterium, that caused valve stenosis. Redo MVR was indicated because of progressive dyspnea and uncontrollable fever. The patient was discharged one month after redo MVR, but suffered carcinomatous peritonitis, and eventually died eight months post-discharge. Chemotherapy needs caution because of potential risk of PVE in patients with prosthetic valves, especially for those with a history of infectious endocarditis.

2024-02-01·HPB

Management and outcomes of hemorrhage after distal pancreatectomy: a multicenter study at high volume centers

Article

作者: Sulpice, Laurent ; Durin, Thibault ; Turrini, Olivier ; Piessen, Guillaume ; El Amrani, Mehdi ; Perinel, Julie ; Doussot, Alexandre ; Gagnière, Johan ; Heyd, Bruno ; Sauvanet, Alain ; Ayav, Ahmet ; Iannelli, Antonio ; Marchese, Ugo ; Regenet, Nicolas ; Facy, Olivier ; Gaujoux, Sébastien ; Souche, François R ; Lenne, Xavier ; Regimbeau, Jean M ; Birnbaum, David J ; Duclos, Côme ; Schwarz, Lilian ; Addeo, Pietro ; Laurent, Christophe

BACKGROUNDData on clinically relevant post-pancreatectomy hemorrhage (CR-PPH) are derived from series mostly focused on pancreatoduodenectomy, and data after distal pancreatectomy (DP) are scarce.METHODSAll non-extended DP performed from 2014 to 2018 were included. CR-PPH encompassed grade B and C PPH. Risk factors, management, and outcomes of CR-PPH were evaluated.RESULTSOverall, 1188 patients were included, of which 561 (47.2 %) were operated on minimally invasively. Spleen-preserving DP was performed in 574 patients (48.4 %). Ninety-day mortality, severe morbidity and CR-POPF rates were 1.1 % (n = 13), 17.4 % (n = 196) and 15.5 % (n = 115), respectively. After a median interval of 8 days (range, 0-37), 65 patients (5.5 %) developed CR-PPH, including 28 grade B and 37 grade C. Reintervention was required in 57 patients (87.7 %). CR-PPH was associated with a significant increase of 90-day mortality, morbidity and hospital stay (p < 0.001). Upon multivariable analysis, prolonged operative time and co-existing POPF were independently associated with CR-PPH (p < 0.005) while a chronic use of antithrombotic agent trended towards an increase of CR-PPH (p = 0.081). As compared to CR-POPF, the failure-to-rescue rate in patients who developed CR-PPH was significantly higher (13.8 % vs. 1.3 %, p < 0.001).CONCLUSIONCR-PPH after DP remains rare but significantly associated with an increased risk of 90-day mortality and failure-to-rescue.

100 项与 MIRX-002 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间皮瘤	临床1期	日本	Hiroshima University	2022-01-20
恶性胸膜间皮瘤	临床1期	日本	PURMX Therapeutics Co. Ltd.	-
头颈部鳞状细胞癌	临床1期	日本	PURMX Therapeutics Co. Ltd.	-